Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBO-154
- Development stage
- Phase 1
- Lead developer
- SPARC
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SBO-154 is a humanized antibody-drug conjugate (ADC) developed by Sun Pharma Advanced Research Company (SPARC) for the treatment of advanced solid tumors. It specifically targets the SEA domain of the tumor-associated antigen MUC1, a glycoprotein broadly expressed on the surface of many carcinomas. SBO-154 binds with high affinity to the MUC1 SEA domain, which is less prone to shedding than other MUC1 regions, and delivers a cytotoxic payload, disrupting microtubules and inhibiting cell division after internalization and cleavage inside tumor cells. The cytotoxic payload and linker are clinically validated components used in several marketed ADCs. The anti-MUC1 antibody component was licensed from Biomodifying, a startup at the University of Tel Aviv. SBO-154 is currently in phase 1 clinical trials for advanced solid tumors[3][4][5][6][7][10].
- Other names
- SBO 154SBO154SBO-154
02
Targets
MUC1 SEA domain (Mucin-1 SEA domain)
Beyond the preview
Go deeper on SBO-154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBO-154.